MediWound Revenue Jumps 43% in Q2

MediWound reported robust Q2 2025 results, with revenue up 43% quarter-over-quarter to $5.7 million and gross margin improving to 23.5%, driven by strong product sales and a favorable mix. The company advanced its EscharEx VALUE Phase III trial, securing strategic partnerships that validate its clinical programs and reduce adoption risk, while NexoBrid sales saw significant growth despite current manufacturing constraints. The new manufacturing facility's on-track completion by year-end 2025, with anticipated EMA and FDA approvals in 2026, is crucial for alleviating supply limitations and unlocking substantial future revenue growth beyond the reaffirmed $24 million 2025 guidance.

Analysis

MediWound (NASDAQ:MDWD) demonstrated strong operational execution in its fiscal second quarter of 2025, reporting a 43% quarter-over-quarter revenue increase to $5.7 million and a significant gross margin improvement to 23.5% from 8.8% in the prior-year period. This financial uplift was driven by higher product sales and a favorable revenue mix. The company's commercial momentum is underscored by its U.S. partner, Vericel, reporting a 52% year-over-year revenue increase for NexoBrid, confirming robust demand that currently outstrips supply, as all production is immediately sold. Concurrently, MediWound is de-risking the future commercialization of its pipeline asset, EscharEx, by expanding strategic partnerships to include wound care leaders ConvaTec and SCT, ensuring its Phase III trials are integrated with all major standard-of-care products. The primary constraint on growth remains manufacturing capacity, with the reaffirmed $24 million revenue guidance for 2025 reflecting this bottleneck. The key inflection point for the company is the new manufacturing facility, which remains on track for completion and regulatory submission by year-end 2025, with anticipated EMA and FDA approvals in 2026 poised to unlock significant revenue expansion.

Key Decisions for Investors

• Investors should view the reaffirmed $24 million revenue guidance for 2025 as a reflection of supply constraints rather than demand limitations, with the potential for a significant revenue inflection in 2026 and beyond.
• The primary catalysts to monitor are the completion of the new manufacturing facility by year-end 2025 and subsequent regulatory approval timelines from the EMA and FDA throughout 2026, as these events are critical to unlocking NexoBrid's sales potential.
• The expanding network of strategic partnerships for the EscharEx clinical program should be considered a key de-risking factor, as it validates the product's integration with existing standards of care and could facilitate wider market adoption upon approval.
• Consider the increased R&D spending of $3.5 million as a necessary investment to advance the late-stage EscharEx trials, which represent a significant long-term value driver for the company.